144 related articles for article (PubMed ID: 30610783)
1. A study on the relationship between chemotherapy-induced cognitive impairment and age in patients with breast cancer.
Liu Z; Han X; Tian C; Chen J; Lei L; Liang Q; Lv X; Tang S; Ning P
J BUON; 2018; 23(6):1601-1605. PubMed ID: 30610783
[TBL] [Abstract][Full Text] [Related]
2. Testing a novel account of the dissociation between self-reported memory problems and memory performance in chemotherapy-treated breast cancer survivors.
Paquet L; Verma S; Collins B; Chinneck A; Bedard M; Song X
Psychooncology; 2018 Jan; 27(1):171-177. PubMed ID: 28129471
[TBL] [Abstract][Full Text] [Related]
3. Differences in prognosis and efficacy of chemotherapy by p53 expression in triple-negative breast cancer.
Bae SY; Nam SJ; Jung Y; Lee SB; Park BW; Lim W; Jung SH; Yang HW; Jung SP
Breast Cancer Res Treat; 2018 Nov; 172(2):437-444. PubMed ID: 30132220
[TBL] [Abstract][Full Text] [Related]
4. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
[TBL] [Abstract][Full Text] [Related]
5. Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.
Ren YX; Hao S; Jin X; Ye FG; Gong Y; Jiang YZ; Shao ZM
Breast; 2019 Feb; 43():97-104. PubMed ID: 30529406
[TBL] [Abstract][Full Text] [Related]
6. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological features and prognosis of triple-negative breast cancer: a comparison between younger (<60) and elderly (≥60) patients.
Qiu JD; Xue XY; Li R; Wang JD
Eur J Cancer Care (Engl); 2016 Nov; 25(6):1065-1075. PubMed ID: 26122025
[TBL] [Abstract][Full Text] [Related]
8. PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients.
Absmaier M; Napieralski R; Schuster T; Aubele M; Walch A; Magdolen V; Dorn J; Gross E; Harbeck N; Noske A; Kiechle M; Schmitt M
Int J Oncol; 2018 Mar; 52(3):755-767. PubMed ID: 29328369
[TBL] [Abstract][Full Text] [Related]
9. Identification of patients with node-negative, triple-negative breast cancer who benefit from adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy.
Wu CE; Chen SC; Lin YC; Lo YF; Hsueh S; Chang HK
Anticancer Res; 2014 Mar; 34(3):1301-6. PubMed ID: 24596377
[TBL] [Abstract][Full Text] [Related]
10. The COMT (rs165599) gene polymorphism contributes to chemotherapy-induced cognitive impairment in breast cancer patients.
Cheng H; Li W; Gan C; Zhang B; Jia Q; Wang K
Am J Transl Res; 2016; 8(11):5087-5097. PubMed ID: 27904710
[TBL] [Abstract][Full Text] [Related]
11. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
12. Folate Receptor Alpha Expression Is Associated With Increased Risk of Recurrence in Triple-negative Breast Cancer.
Ginter PS; McIntire PJ; Cui X; Irshaid L; Liu Y; Chen Z; Shin SJ
Clin Breast Cancer; 2017 Nov; 17(7):544-549. PubMed ID: 28410844
[TBL] [Abstract][Full Text] [Related]
13. Prognosis in different subtypes of metaplastic breast cancer: a population-based analysis.
He X; Ji J; Dong R; Liu H; Dai X; Wang C; Esteva FJ; Yeung SJ
Breast Cancer Res Treat; 2019 Jan; 173(2):329-341. PubMed ID: 30341462
[TBL] [Abstract][Full Text] [Related]
14. Mutational analysis of triple-negative breast cancers within the International Breast Cancer Study Group (IBCSG) Trial 22-00.
Munzone E; Gray KP; Fumagalli C; Guerini-Rocco E; Láng I; Ruhstaller T; Gianni L; Kammler R; Viale G; Di Leo A; Coates AS; Gelber RD; Regan MM; Goldhirsch A; Barberis M; Colleoni M
Breast Cancer Res Treat; 2018 Jul; 170(2):351-360. PubMed ID: 29589138
[TBL] [Abstract][Full Text] [Related]
15. BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.
Akashi-Tanaka S; Watanabe C; Takamaru T; Kuwayama T; Ikeda M; Ohyama H; Mori M; Yoshida R; Hashimoto R; Terumasa S; Enokido K; Hirota Y; Okuyama H; Nakamura S
Clin Breast Cancer; 2015 Feb; 15(1):80-5. PubMed ID: 25445419
[TBL] [Abstract][Full Text] [Related]
16. Prospective comparison of outcome after treatment for triple-negative and non-triple-negative breast cancer.
Joyce DP; Murphy D; Lowery AJ; Curran C; Barry K; Malone C; McLaughlin R; Kerin MJ
Surgeon; 2017 Oct; 15(5):272-277. PubMed ID: 28277293
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy in pT1ab node-negative triple-negative breast carcinomas: Results of a national multi-institutional retrospective study.
de Nonneville A; Gonçalves A; Zemmour C; Cohen M; Classe JM; Reyal F; Colombo PE; Jouve E; Giard S; Barranger E; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
Eur J Cancer; 2017 Oct; 84():34-43. PubMed ID: 28780480
[TBL] [Abstract][Full Text] [Related]
18. Change in sonographic brightness can predict pathological response of triple-negative breast cancer to neoadjuvant chemotherapy.
Matsuda N; Kida K; Ohde S; Suzuki K; Yamauchi H; Nakamura S; Tsunoda H
Breast Cancer; 2018 Jan; 25(1):43-49. PubMed ID: 28536943
[TBL] [Abstract][Full Text] [Related]
19. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
[TBL] [Abstract][Full Text] [Related]
20. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
Rashid MU; Muhammad N; Bajwa S; Faisal S; Tahseen M; Bermejo JL; Amin A; Loya A; Hamann U
BMC Cancer; 2016 Aug; 16(1):673. PubMed ID: 27553291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
